Critical Outcome Technologies Inc.

Critical Outcome Technologies Inc.

January 18, 2007 14:02 ET

Critical Outcome Technologies Inc. Announces the Issuance of Stock Options

LONDON, ONTARIO--(CCNMatthews - Jan. 18, 2007) - Critical Outcome Technologies Inc. (TSX VENTURE:COT) announces today, under the Company's Stock Option Plan, the Board of Directors approved the granting of 50,000 stock options to senior management exercisable at a price of $0.70 per share for a period of 5 years from the date of the grant. One-sixth of these stock options vest immediately and one-sixth vest every six months until complete vesting on July 17, 2009. The exercise price represents the closing price of the Company's common shares on January 11, 2007, as reported on the TSX Venture Exchange.

Stock options enhance the Company's ability to attract and retain talented people by providing compensation incentives to employees, directors, officers and consultants for future services provided to the Company.

About Critical Outcome Technologies Inc. (COTI)

COTI is formed around a unique computational platform technology called CHEMSAS®, which allows for the accelerated identification, profiling and optimization of targeted small molecules potentially effective in the treatment of human diseases for which current therapy is either lacking or ineffective. COTI's business is focused on the discovery and pre-clinical development of libraries of novel, optimized lead molecules for the treatment of specific cancers, HIV and multiple sclerosis. Currently, five targeted libraries of lead compounds (small cell lung cancer, multiple sclerosis, HIV integrase inhibitors, colorectal cancer, and acute myelogenous leukemia in adults) are under active development. For more information on COTI, please visit

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information